Genomica Corporation Appoints Michael ``Mick'' J. Savage to its Board of Directors.

Business Editors & Health/Medical Writers

BIOWIRE2K

BOULDER, Colo.--(BW HealthWire)--June 19, 2001

Genomica Corporation (Nasdaq: GNOM), a leading bioinformatics company developing software tools to facilitate gene discovery and drug development, today announced the appointment of Michael ("Mick") J. Savage to its Board of Directors.

Mr. Savage brings to the Board over 24 years of executive experience in the pharmaceutical and life sciences industries, most recently including eight years as the Chief Executive Officer and President of Molecular Simulations Inc., which was acquired by Pharmacopeia in 1998. Mr. Savage will fill the Board seat being vacated by Dr. Arnold J. Levine, who is joining Genomica's Scientific Advisory Board.

"Mick brings to our Board of Directors a tremendous amount of experience and success in the biotechnology industry," stated Teresa W. Ayers, Chief Executive Officer of Genomica. "His broad experience and knowledge of biology, chemistry and information technology for pre-clinical research and development will help us as we expand our product offerings and functionality across the drug development continuum."

"I am very pleased to join Genomica at this exciting juncture," said Mr. Savage, Principal of Savage Consulting. "Genomica's bioinformatics tools will enable the biotechnology and pharmaceutical industries to more rapidly and efficiently apply genomic data, accelerating drug discovery and increasing the success of clinical trials."

Prior to Savage Consulting, Mr. Savage was Chief Executive Officer and President of Molecular Simulations Inc. from 1991 until the company was acquired by Pharmacopeia in 1998, at which time he became Executive Vice President and a member of the Board of Directors of Pharmacopeia. Mr. Savage received a Bachelor of Science in Chemistry and Biology from Fort Lewis College and a Masters in Biology from the California Institute of Technology.

About Genomica Corporation

Genomica Corporation develops and markets innovative software products and services, which enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process. Genomica's current customers include leading genomics-based research organizations such as AstraZeneca, GlaxoSmithKline, Aventis, Pfizer and the National Cancer Institute. Genomica is also collaborating with Applied Biosystems to develop software products to be used with its industry-leading hardware for drug discovery. For additional information on Genomica, please visit our Web site at www.genomica.com.

Certain statements in this press release are forward looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on Genomica Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Genomica Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Such factors include, but are not limited to, quarterly fluctuations in Genomica's revenues or other operating results, failure by Genomica to meet financial expectations of analysts and investors, reliance by Genomica on a limited number of customers for a majority of its revenue, Genomica's reliance on key personnel, risks as related to market acceptance of Genomica's product, rapid technological change in Genomica's market, potential defects associated with Genomica's product, Genomica's need to maintain and enhance strategic relationships with larger companies, Genomica's ability to expand its sales and marketing departments, Genomica's ability to manage growth, Genomica's use in its product of third-party components, activities by Genomica and others regarding protection of intellectual property, release of competitive products and other actions by competitors, and economic downturns in either domestic or foreign markets. Further details on these risks and other risks are set forth in Genomica's filings with the Securities and Exchange Commission. These filings are available on a web site maintained by the Securities and Exchange Commission on the world wide web at www.sec.gov. Genomica does not undertake an obligation to update forward-looking statements.